Guggenheim Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $450
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Vertex Pharmaceuticals (VRTX) and raises the price target from $445 to $450.
April 18, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay reaffirms a Buy rating on Vertex Pharmaceuticals and increases the price target to $450.
The increase in price target by a reputable analyst like Debjit Chattopadhyay signals a strong confidence in Vertex Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100